Attached files
| file | filename |
|---|---|
| 10-K - 10-K - NeuroBo Pharmaceuticals, Inc. | nrbo-20201231x10k.htm |
| EX-31.1 - EX-31.1 - NeuroBo Pharmaceuticals, Inc. | nrbo-20201231ex311f8c49a.htm |
| EX-23.1 - EX-23.1 - NeuroBo Pharmaceuticals, Inc. | nrbo-20201231ex231b42d26.htm |
| EX-21.1 - EX-21.1 - NeuroBo Pharmaceuticals, Inc. | nrbo-20201231ex21121ead2.htm |
| EX-10.40 - EX-10.40 - NeuroBo Pharmaceuticals, Inc. | nrbo-20201231ex1040bc0cf.htm |
| EX-4.5 - EX-4.5 - NeuroBo Pharmaceuticals, Inc. | nrbo-20201231ex4549cc3b5.htm |
Exhibit 32.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of NeuroBo Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission (the “Report”), I, Richard Kang, President, Chief Executive Officer and Interim Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
April 15, 2021 /s/ Richard Kang |
Richard Kang |
President, Chief Executive Officer and Interim Chief Financial Officer (Principal Executive Officer and Principal Financial Officer) |